Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer
Cantargia today presented interim efficacy data for 39 non-small cell lung cancer patients treated with nadunolimab and platinum-based chemotherapy as a poster at the ASCO Annual Meeting 2023 , and... | June 4, 2023